These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 325424)

  • 1. Analysis of the results of treament of lung cancer patients with BCG according to the scheme of application of the bacillus.
    Hadziev S; Kavaklieva-Dimitrova J
    Neoplasma; 1977; 24():225-31. PubMed ID: 325424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial.
    Matthay RA; Mahler DA; Beck GJ; Loke J; Baue AE; Carter DC; Mitchell MS
    Cancer Res; 1986 Nov; 46(11):5963-8. PubMed ID: 3530442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of lung cancer patients treated with BCG and/or a soluble BCG fraction (F70) after surgery, radiotherapy and chemotherapy.
    Hadźiev S; Kavaklieva-Dimitrova J; Mandulova P; Madźarova S; Spassova M
    Neoplasma; 1980; 27(1):83-94. PubMed ID: 7374861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
    Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
    Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCG immunotherapy of lung cancer in a district oncology dispensary. I. Study of 860 patients with histologic diagnosis.
    Hadźiev S; Mandulova P; Kavaklieva-Dimitrova J; Penev K; Spassova M; Madźarova S
    Neoplasma; 1982; 29(1):93-110. PubMed ID: 6280082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
    Winters WD; Lamm DL
    Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy of lung cancer using BCG cell-wall skeleton].
    Yasumoto K
    Kekkaku; 1977 Oct; 52(10):530-1. PubMed ID: 340747
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of malignant melanoma by intratumoral injection of BCG.
    Pinsky CM; Hirshaut Y; Oettgen HF
    Natl Cancer Inst Monogr; 1973 Dec; 39():225-8. PubMed ID: 4595322
    [No Abstract]   [Full Text] [Related]  

  • 14. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in biological activity among batches of lyophilized tice Bacillus Calmette-Guérin and their association with clinical course in Stage I lung cancer.
    Bennett JA; Gruft H; McKneally MF; Zelterman D; Crispen RG
    Cancer Res; 1983 Sep; 43(9):4183-90. PubMed ID: 6347367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCG immunotherapy of rat tumors of defined immunogenicity.
    Baldwin RW; Pimm MV
    Natl Cancer Inst Monogr; 1973 Dec; 39():11-9. PubMed ID: 4595312
    [No Abstract]   [Full Text] [Related]  

  • 17. Intrapleural BCG in postsurgical stage I non-small cell lung cancer.
    Macchiarini P; Mussi A; Angeletti CA
    Anticancer Res; 1989; 9(2):391-3. PubMed ID: 2546484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy by BCG against prostate adenocarcinomas in anatomical compartments.
    Pollard M; Luckert PH
    Anticancer Res; 1994; 14(6B):2691-4. PubMed ID: 7872703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunologic capacity of cancer patients and BCG-CSW immunotherapy].
    Yasumoto K; Manabe H; Yanagawa E; Nagano S; Ueda H
    Nihon Kyobu Geka Gakkai Zasshi; 1979 Apr; 27(4):449-51. PubMed ID: 381535
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic effect of a water-salt extract from BCG in two patients with advanced breast cancer.
    Hadziev S; Kavaklieva-Dimtrova J; Mandulova P
    Neoplasma; 1975; 22(3):269-72. PubMed ID: 1099468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.